Symposia: Acute Lymphoblastic Leukemias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Biological therapies, clinical trials, adult, Translational Research, Combination therapy, Clinical Research, drug development, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Study Population, Human, Transplantation, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Biological therapies, clinical trials, adult, Translational Research, Combination therapy, Clinical Research, drug development, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Study Population, Human, Transplantation, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
243-245
(Ernest N. Morial Convention Center)
Moderators:
Hiroto Inaba, MD, PhD, St. Jude Children's Research Hospital
and
Deborah Yallop, MBBS, FRCP, FRCPATH, PHD, King's College Hospital NHS Trust
Disclosures:
Yallop: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Other: Meeting support, Research Funding; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Meeting Support.
This acute lymphoblastic leukemia (ALL)-focused session includes globally represented abstracts encompassing children, adolescents, young adults and the elderly. Abstracts in this session report the results of important clinical studies aimed at improving outcomes among particularly difficult to treat subsets of both B- and T-cell ALL. The findings highlight important approaches to improved risk stratification leveraging clinical factors, genomics and minimal residual disease. Novel approaches to therapy are explored including intensification of standard chemotherapy, pediatric inspired chemotherapy regimens for elderly adults and the addition of nelarabine plus intensification of asparaginase for adults with T-ALL. The results presented in this session lend support to the idea that for pediatric ALL, we have likely hit the ceiling of therapy intensification as a means to further improve outcomes. Data presented in this session also reveal that among adults with ALL, through refined age- and risk-adapted therapy, further improvements in outcome may be attainable.
9:30 AM
9:45 AM
10:00 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH